about
Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease.Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysisEvaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients.Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis.Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease.Apoptosis: why and how does it occur in biology?Cytokeratins in hepatitis.NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk.Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials.Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease.Liver disease and malnutrition.Obesity-associated nonalcoholic fatty liver disease.Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease.Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance.Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: tools or decorations?Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments.Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease.Metformin, hepatitis C, and insulin resistance: sufficient evidence?Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis.Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease.Assessment of endothelial function in patients with nonalcoholic fatty liver disease.Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease.Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis.Folic Acid and vitamin B12 supplementation improves coronary flow reserve in elderly subjects with vitamin B12 deficiency.Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease.The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity.Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease.Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels.Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease.Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia.Psychopathology in the context of obesity: the adiponectin hypothesis.Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis.Acute arsenic self-poisoning for suicidal purpose in a dentist: a case report.
P50
Q33514542-3761F86C-7591-4F54-88EA-0112BD3C45AEQ33633689-F6ED5108-32F3-4D3B-8324-777B7CAF5B1CQ33932951-0C37EBF7-E6FC-4FCA-8E4A-49EA65DB4AB0Q34606222-7F0D98BF-359E-4FD2-AA28-1E47571960A0Q36561556-9D7F3739-D21C-481A-AFBE-82014A36531EQ37262078-CB0169CD-2AF5-4963-8FC3-1680520DC3BEQ37600924-E7B31A66-B0FA-47B0-B242-335FFAB359DFQ37902996-B8A052DD-3C7E-432C-985C-8A93ED52BEECQ37933852-7B945342-1D61-4E33-9359-540DA943F336Q37993756-162D7953-3D17-4F33-841A-3EEA405533A8Q38021479-F76CC6D4-9672-4992-85C7-E89CF55EA6ADQ38135937-12FCED81-7DE2-4DC6-96F0-5EB9AA28E916Q38136292-A3A39352-A722-4346-BC54-71FCE7170E2CQ38148872-4B144DA1-C1D3-4D83-ABC6-78748C7B5BC0Q38166052-B2813699-43F4-47FF-AF32-3849389A0121Q39770363-10071D94-A7F7-4A00-9758-2A10C5DAEB31Q39976329-043536E7-75D2-43AE-85BB-9A9CE0F2C2D2Q42555756-1DA3A91F-A8E7-43CC-86AE-D7C88EA02059Q42859204-336283F9-E19A-4708-A86F-6B837E338850Q42972684-D09B7004-F375-4533-913E-75A0A605FDBDQ43235919-373B7579-4676-4914-9765-6D97D5C8B7B8Q43285463-98898597-0321-4C7A-A98D-F8C48C3A550CQ43448506-A1AB7BEB-E77A-4BF6-9EC1-732709637B70Q43654066-91FAE45C-A9D4-4BCC-B4A9-B98FDDFDBECBQ43663978-42218FBB-8379-4007-B27F-DEBADD72A042Q43905854-4D34A96D-2492-460F-9E3D-3D3577B2F79AQ44639136-68311713-4C89-4390-ABBA-A3206CF7B0E1Q45200394-4E9579A7-3E2E-4B39-B2AA-C0641E80D375Q45582892-658B248B-41E6-495B-B1CC-00B232C79FBFQ45763508-3C64F23D-0067-4C40-98DE-E9C52275384AQ45819487-1B965995-BC9C-4F27-A354-9D3E48520DECQ46032025-CD364AE0-7BDF-453C-93ED-F7878D4F1915Q46165943-EAE27178-0925-4B20-8F98-D530811DB612Q46227426-D7D4B121-DD74-4524-B15F-BCC67EAC73E4Q46364576-5155D8B5-2A94-460F-A08F-3602E39AE845Q46525535-D0F1A6B2-66AD-4CAA-BA40-A97B4B1FEFB5Q46664435-7087E1D7-93FB-499D-B506-312CE469FA15Q46963191-CB426E08-BC7E-4349-B84A-E42394664743Q47284906-55DA6C11-4F64-4FF0-AE5D-B86C374A1748Q47598426-D6B8BAEC-4D95-4CD4-889E-11CFD4C42D8F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yusuf Yilmaz
@ast
Yusuf Yilmaz
@es
Yusuf Yilmaz
@nl
Yusuf Yilmaz
@sl
Yusuf Yılmaz
@en
type
label
Yusuf Yilmaz
@ast
Yusuf Yilmaz
@es
Yusuf Yilmaz
@nl
Yusuf Yilmaz
@sl
Yusuf Yılmaz
@en
prefLabel
Yusuf Yilmaz
@ast
Yusuf Yilmaz
@es
Yusuf Yilmaz
@nl
Yusuf Yilmaz
@sl
Yusuf Yılmaz
@en
P106
P1153
22936014300
P21
P31
P496
0000-0003-4518-5283
P6100
D77686936C925E44